Offering SPR-BLI Services - Proteins provided for free! Here come GMP Grade Cytokines!Free Sample is available!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Cynomolgus IL-2RB&IL-2RA&IL-2RG Protein, His Tag&Twin-Strep Tag (Cat. No. ILG-C52W3) captured on CM5 chip via anti-His antibody can bind Human IL-2, Tag Free with an affinity constant of 29.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Lymphoma, Mantle-Cell; Leprosy, Lepromatous; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Carcinoma, Adenosquamous; Cholangitis, Sclerosing; Osteosarcoma; Endometrial Neoplasms; Xerostomia; Gastrointestinal Hemorrhage; Sarcoma, Ewing; HIV Wasting Syndrome; Pancreatitis, Chronic; Arachnoiditis; Retinoblastoma; Erythema Nodosum; Prostatic Neoplasms; Drug Resistant Epilepsy; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Sarcoma; Angiodysplasia; Lymphoma, Non-Hodgkin; Appendiceal Neoplasms; Pelvic Pain; Waldenstrom Macroglobulinemia; Glioma; Uterine Neoplasms; Anemia, Sideroblastic; Lung Neoplasms; Mycobacterium Infections; Lupus Erythematosus, Discoid; Anemia, Refractory, with Excess of | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
DF-6215 | DF6215; DF-6215 | Phase 1 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
VIS171 | VIS-171; VIS171 | Phase 1 Clinical | Visterra Inc | Autoimmune Diseases | Details |
SHR-1916 | SHR-1916 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours | Details |
RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
SAR-444336 | SAR-444336 | Phase 1 Clinical | Sanofi | Inflammation | Details |
STK-012 | STK-012 | Phase 1 Clinical | Synthekine Inc | Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
AB-248 | AB-248 | Phase 1 Clinical | Asher Biotherapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
SIM-0278 | ALM-223; SIM0278 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic | Details |
M5A-IL2 Immunocytokine | M5A-ICK | Phase 1 Clinical | National Cancer Institute, City Of Hope National Medical Center | Breast Neoplasms; Colorectal Neoplasms | Details |
Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Igrelimogene litadenorepvec | PM-1016; PM1016; TILT-123 | Phase 1 Clinical | Tilt Biotherapeutics Ltd | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details |
attIL2-T cell therapy | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Soft Tissue Neoplasms; Osteosarcoma; Sarcoma | Details | |
Dodekin | Phase 1 Clinical | Philogen Spa | Solid tumours; Neoplasm Metastasis | Details | |
T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
XTX-202 | XTX-202 | Phase 2 Clinical | Xilio Development Inc, Xilio Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Melanoma | Details |
ASP-1012 | VET2-L2; ASP-1012; ASP1012 | Phase 1 Clinical | KaliVir Immunotherapeutics Inc | Solid tumours | Details |
AVB-001 | AVB-001 | Phase 2 Clinical | Avenge Bio Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
KB-707 | KB-707; KB707 | Phase 1 Clinical | Krystal Biotech Inc | Skin Melanoma; Carcinoma, Basal Cell; Neoplasms; Osteosarcoma; Carcinoma, Squamous Cell; Melanoma | Details |
Saltikva | Phase 2 Clinical | Salspera LLC | Pancreatic Neoplasms | Details | |
AU-007 | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
umitrelimorgene autodencel | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
MK-1484 | MK-1484; SP-482 | Phase 1 Clinical | Merck & Co Inc, Sutro Biopharma Inc | Solid tumours | Details |
BNT-153 | BNT-153 | Phase 1 Clinical | Biontech Se | Solid tumours | Details |
RS-2102 | RS2102 | Phase 1 Clinical | Reistone Biopharma Co Ltd | Dermatitis, Atopic | Details |
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
Mableukin 2PD1(Anwita Biosciences) | AWT020; AWT-020 | Phase 1 Clinical | Anwita Biosciences Inc | Neoplasms; Autoimmune Diseases of the Nervous System | Details |
BNZ-1 | BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic | Details |
This web search service is supported by Google Inc.